血清JAK-STAT信号通路相关蛋白对类风湿性关节炎患者的预后评估

doi:10.3760/cma.j.cn441417-20241030-06016

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (6): 960-964.DOI: 10.3760/cma.j.cn441417-20241030-06016

血清JAK-STAT信号通路相关蛋白对类风湿性关节炎患者的预后评估

张雪锋¹ 吕艳艳² 戴璐³

¹陕西省中西医结合医院西安市第五医院骨质疏松科，西安 710082；²陕西省中西医结合医院西安市第五医院风湿免疫科，西安 710082；³陕西省中西医结合医院西安市第五医院风湿免疫骨松科，西安 710082

收稿日期:2024-10-30 出版日期:2025-03-15 发布日期:2025-03-17
通讯作者: 戴璐，Email：lulu851105@sina.com
基金资助:
陕西省自然科学基础研究计划（2023-JC-YB-765）

Serum JAK-STAT signaling pathway related proteins assessment of prognosis in patients with rheumatoid arthritis

Zhang Xuefeng¹, Lyu Yanyan², Dai Lu³

¹Department of Osteoporosis, Shaanxi Integrated Traditional Chinese and Western Medicine Hospital, Xi 'an Fifth Hospital, Xi'an 710082, China; ²Department of Rheumatology and Immunology, Shaanxi Integrated Traditional Chinese and Western Medicine Hospital, Xi 'an Fifth Hospital, Xi'an 710082, China; ³Department of Rheumatology, Immunology, and Osteoporosis, Shaanxi Integrated Traditional Chinese and Western Medicine Hospital, Xi 'an Fifth Hospital, Xi'an 710082, China

Received:2024-10-30 Online:2025-03-15 Published:2025-03-17
Contact: Dai Lu, Email: lulu851105@sina.com
Supported by:
Basic Research Plan of Natural Science in Shaanxi (2023-JC-YB-765)

摘要/Abstract

摘要：

目的　探讨血清中Janus激酶（janus kinase，JAK）-转录活化因子（signal transducer and activator of transcription，STAT）信号通路相关蛋白在类风湿性关节炎患者预后评估中的价值。方法　研究对象为陕西省中西医结合医院于2022年1月至2024年1月收治的类风湿性关节炎患者，共纳入118例，所有患者均在入组后检测血清JAK-STAT信号通路相关蛋白JAK、STAT3的表达量及炎性因子水平［肿瘤坏死因子-α（TNF-α）、白细胞介素（IL）-1β、IL-6、巨噬细胞移动抑制因子（MIF）］。给予甲氨蝶呤和醋酸泼尼松治疗4周后，根据患者病情缓解情况分为预后良好组和预后不良组。预后良好组中男49例、女34例，年龄（38.45±4.72）岁；预后不良组中男22例、女14例，年龄（38.73±4.88）岁。比较两组各检测指标水平，通过logistic回归分析筛选预后不良的风险因素，并采用受试者操作特征曲线（ROC）评估血清JAK、STAT3表达水平对类风湿性关节炎预后的诊断价值，采用t、χ²检验进行统计学比较。结果　118例类风湿性关节炎患者中，预后不良35例（29.66%）。预后不良组治疗前的血清JAK、STAT3 mRNA水平分别为1.61±0.35、1.55±0.34，高于预后良好组（1.34±0.28、1.30±0.26），差异均有统计学意义（均P<0.05）。预后不良组治疗前的TNF-α、IL-1β、IL-6、MIF分别为（65.82±7.13、20.17±3.42、28.56±4.02、20.39±3.15）μg/L，均高于预后良好组［（58.42±6.36、15.24±2.39、23.30±3.19、16.42±2.48）μg/L］，差异均有统计学意义（均P<0.05）。Logistic回归分析显示，治疗前JAK、STAT3 mRNA和炎性因子水平均是影响预后的重要因素（均P<0.05）。ROC显示，JAK联合STAT3预测类风湿性关节炎患者预后不良的曲线下面积为0.809。结论　JAK-STAT信号通路在类风湿性关节炎中起重要作用，影响治疗效果和预后。

关键词:

JAK-STAT信号通路, 类风湿性关节炎, 预后

Abstract:

Objective　To explore the value of serum Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signaling pathway markers in the assessment of the prognosis in patients with rheumatoid arthritis. Methods　From January 2022 to January 2024, 118 patients with rheumatoid arthritis treated at Shaanxi Integrated Traditional Chinese and Western Medicine Hospital were enrolled. After the enrollment, the serum levels of JAK and STAT3 proteins and the levels of inflammatory markers [tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), IL-6, and macrophage migration inhibitory factor (MIF)] were measured. The patients were treated with methotrexate and prednisone acetate for 4 weeks, and their conditions was evaluated. Based on the improvement in symptoms, the patients were categorized into a good prognosis group and a poor prognosis group. There were 49 males and 34 females in the good prognosis group; they were (38.45±4.72) years old. There were 22 males and 14 females in the poor prognosis group; they were (38.73±4.88) years old. The levels of the markers were compared between the two groups. The logistic regression analysis was used to identify the risk factors for poor prognosis. The diagnostic value of serum JAK and STAT3 expression levels for predicting outcomes was assessed using the receiver operating characteristic curve (ROC). t and χ² tests were used for the statistical analysis. Results　Among the 118 patients, 35 (29.66%) had poor prognosis. Before the treatment, the serum levels of JAK and STAT3 in the poor prognosis group were higher than those in the good prognosis group (1.61±0.35 vs. 1.34±0.28 and 1.55±0.34 vs. 1.30±0.26), with statistical differences (both P<0.05). The levels of TNF-α, IL-1β, IL-6, and MIF in the poor prognosis group before the treatment were higher than those in the good prognosis group [(65.82±7.13) μg/L vs. (58.42±6.36) μg/L, (20.17±3.42) μg/L vs. (15.24±2.39) μg/L, (28.56±4.02) μg/L vs. (23.30±3.19) μg/L, and (20.39±3.15) μg/L vs. (16.42±2.48) μg/L], with statistical differences (all P<0.05). The logistic regression analysis showed that the levels of JAK, STAT3, and inflammatory factors before the treatment were significant predictors of their prognosis (all P<0.05). ROC showed that the area under the curve of JAK combined with STAT3 predicted poor prognosis in rheumatoid arthritis patients was 0.809. Conclusion　The JAK-STAT signaling pathway plays a significant role in rheumatoid arthritis, and may influence the treatment outcomes and prognosis.

Key words:

JAK-STAT signaling pathway, Rheumatoid arthritis, Prognosis

张雪锋吕艳艳戴璐.

血清JAK-STAT信号通路相关蛋白对类风湿性关节炎患者的预后评估 [J]. 国际医药卫生导报, 2025, 31(6): 960-964.

Zhang Xuefeng, Lyu Yanyan, Dai Lu.

Serum JAK-STAT signaling pathway related proteins assessment of prognosis in patients with rheumatoid arthritis [J]. International Medicine and Health Guidance News, 2025, 31(6): 960-964.

参考文献

[1] 赵军一,赵凤,曲冰佳,等. 1990-2019年中国类风湿性关节炎疾病负担现状和趋势分析[J]. 中国卫生统计,2024,41(3):344-348,353. DOI:10.11783/j.issn.1002-3674.2024. 03.004.
[2] 余丽君,潘歆,詹爱琴,等. 类风湿性关节炎患者合并潜伏性结核感染危险因素及Treg、Th17的预测价值[J]. 中华医院感染学杂志,2023,33(17):2600-2604. DOI:10.11816/cn.ni.2023-230107.
[3] Maeda K, Yoshida K, Nishizawa T, et al. Inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments[J]. Int J Mol Sci, 2022,23(5):2871. DOI: 10.3390/ijms23052871.
[4] 梁霄,李娅兰,张筠昊,等. 用于治疗类风湿性关节炎的微针经皮给药系统研究进展[J]. 中国中药杂志,2023,48(1):13-21. DOI:10.19540/j.cnki.cjcmm.20221013.601.
[5] Patel AV, Morgan SL, Green R, et al. Vitamin B12 status and hyperhomocysteinemia in patients with Rheumatoid arthritis treated with methotrexate and folic acid[J]. Am J Med Sci, 2024, 368(1):33-39. DOI: 10.1016/j.amjms. 2024.03.020.
[6] 黄懿敏,谭志明,庄宇. 外周血T淋巴细胞亚群与联合糖皮质激素治疗后类风湿性关节炎患者预后的关系[J]. 广西医学,2022,44(24):2841-2846. DOI:10.11675/j.issn. 0253-4304.2022.24.02.
[7] 肖凡妮,青玉凤,张全波. JAK/STAT信号通路在风湿免疫性疾病中作用的研究进展[J]. 中国全科医学,2022,25(17):2159-2164. DOI:10.12114/j.issn.1007-9572.2022.0275.
[8] Guo X, Ji J, Zhang J, et al. Anti-inflammatory and osteoprotective effects of Chikusetsusaponin Ⅳa on rheumatoid arthritis via the JAK/STAT signaling pathway[J]. Phytomedicine, 2021, 93:153801. DOI: 10.1016/j.phymed.2021.153801.
[9] Kour G, Choudhary R, Anjum S, et al. Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: is there a future?[J]. Biochem Pharmacol, 2022, 197:114929. DOI: 10.1016/j.bcp.2022.114929.
[10] 雷海桃,田雪梅,金芳全. 细胞因子信号转导抑制因子与类风湿关节炎的相关性研究进展[J]. 上海交通大学学报(医学版),2022,42(7):945-951. DOI:10.3969/j.issn. 1674-8115.2022.07.015.
[11] 中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志,2018,57(4):242-251. DOI:10.3760/cma.j.issn.0578-1426.2018.04.004.
[12] Ramon Haddad PA, Vargas-Santos AB, Silva Freire Coutinho E, et al. Performance of the rheumatoid arthritis disease activity index in the assessment of disease activity in rheumatoid arthritis-findings from the REAL study[J]. J Clin Rheumatol, 2022, 28(4):206-211. DOI: 10.1097/RHU.0000000000001834.
[13] Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis[J]. J Autoimmun, 2020, 110:102400. DOI: 10.1016/j.jaut.2019.102400.
[14] 罗玲,李梓成,梁国艳,等. 类风湿性关节炎中红细胞体积分布宽度及相关炎性因子的相关性分析[J]. 岭南急诊医学杂志,2023,28(6):550-552. DOI:10.3969/j.issn. 1671-301X. 2023.06.008.
[15] 姬东波,杨珊珊. 血清中抗核周因子(APF),抗角蛋白抗体(AKA)及抗环瓜氨酸多肽(CCP)抗体在类风湿性关节炎(RA)诊断中的应用价值[J]. 航空航天医学杂志,2024,35(1):54-57. DOI:10.3969/j.issn.2095-1434.2024.01.019.
[16] 荀春华,江代红,瞿俊. 磁微粒化学发光法检测抗RA-33、抗CCP抗体及类风湿因子的临床应用评估[J]. 中国免疫学杂志,2023,39(11):2393-2396. DOI:10.3969/j.issn. 1000-484X.2023.11.026.
[17] Zhou J, Huang W, Zhang Z, et al. Cause analysis of conversion to biologics in spondyloarthritis patients with poor response to conventional treatment[J]. Clin Rheumatol, 2023, 42(12):3251-3255. DOI: 10.1007/s10067-023-06724-3.
[18] Vittecoq O, Brevet P, Gerard B, et al. On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis[J]. RMD Open, 2024, 10(3):e004472. DOI: 10.1136/rmdopen-2024-004472.
[19] Baldini C, Moriconi FR, Galimberti S, et al. The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms[J]. Eur Heart J, 2021, 42(42):4389-4400. DOI: 10.1093/eurheartj/ehab447.
[20] Wang X, Cao W, Sun C, et al. Development of pH-sensitive dextran-based methotrexate nanodrug for rheumatoid arthritis therapy through inhibition of JAK-STAT pathways[J]. Int J Pharm, 2022, 622:121874. DOI: 10.1016/j.ijpharm.2022.121874.
[21] 许炬珍,张丽卿. JAK/STAT信号通路在类风湿关节炎致病机制及治疗靶点中的作用进展[J]. 河北医药,2024,46(4):601-605,611. DOI:10.3969/j.issn.1002-7386.2024.04.028.
[22] 张慧杰,柴立民,刘娟,等. 基于JAK/STAT信号通路探讨红茴香注射液对类风湿关节炎小鼠的作用机制[J]. 北京中医药大学学报,2022,45(3):267-274. DOI:10.3969/j.issn.1006-2157.2022.03.010.
[23] Wang Z, Zhan C, Zeng F, et al.A biopolymer-based and inflammation-responsive nanodrug for rheumatoid arthritis treatment via inhibiting JAK-STAT and JNK signalling pathways[J]. Nanoscale, 2020, 12(45):23013-23027. DOI: 10.1039/d0nr05551d.
[24] Xiao T, Cheng X, Zhi Y, et al. Ameliorative effect of Alangium chinense (Lour.) Harms on rheumatoid arthritis by reducing autophagy with targeting regulate JAK3-STAT3 and COX-2 pathways[J]. J Ethnopharmacol, 2024, 319 Pt 1:117133. DOI: 10.1016/j.jep.2023.117133.
[25] Alvarez AM, DeOcesano-Pereira C, Teixeira C, et al. IL-1β and TNF-α modulation of proliferated and committed myoblasts: IL-6 and COX-2-derived prostaglandins as key actors in the mechanisms involved[J]. Cells, 2020, 9(9):2005. DOI: 10.3390/cells9092005.
[26] Papadaki G, Goutakoli P, Tiniakou I, et al. IL-6 signaling attenuates TNF-α production by plasmacytoid dendritic cells in rheumatoid arthritis[J]. J Immunol, 2022, 209(10):1906-1917. DOI: 10.4049/jimmunol.2100882.
[27] Feng W, Yang P, Liu H, et al. IL-6 promotes low concentration of RANKL-induced osteoclastic differentiation by mouse BMMs through trans-signaling pathway[J]. J Mol Histol, 2022, 53(3):599-610. DOI: 10.1007/s10735-022-10077-7.
[28] 尚娟. 加味愈痛丸治疗强直性脊柱炎疗效观察及对血清JAK/STAT信号通路的影响[J]. 新中医,2023,55(21):77-82. DOI:10.13457/j.cnki.jncm.2023.21.015.
[29] Park JW, Lee HS, Lim Y, et al. Rhododendron album Blume extract inhibits TNF-α/IFN-γ-induced chemokine production via blockade of NF-κB and JAK/STAT activation in human epidermal keratinocytes[J]. Int J Mol Med, 2018, 41(6):3642-3652. DOI: 10.3892/ijmm. 2018.3556.
[30] Li X, Yu M, Chen L, et al. Retraction notice to "LncRNA PMS2L2 protects ATDC5 chondrocytes against lipopolysaccharide-induced inflammatory injury by sponging miR-203" [Life Sci. 217 (2018) 283-292][J]. Life Sci, 2022, 299:120535. DOI: 10.1016/j.lfs.2022.120535.
[31] Guo X, Ji J, Zhang J, et al. Anti-inflammatory and osteoprotective effects of Chikusetsusaponin Ⅳa on rheumatoid arthritis via the JAK/STAT signaling pathway[J]. Phytomedicine, 2021, 93:153801. DOI: 10.1016/j.phymed.2021.153801.

血清JAK-STAT信号通路相关蛋白对类风湿性关节炎患者的预后评估

Serum JAK-STAT signaling pathway related proteins assessment of prognosis in patients with rheumatoid arthritis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李勇平吴水淼焦亲任佳辉张潇. 血清Syndecan-1、Endocan-1、GRP78与老年重症肺炎并发ARDS患者病情及预后的关系 [J]. 国际医药卫生导报, 2025, 31(7): 1173-1178.
[2]	张进萍陈玲黄震宇王颖黄晓玲黄豪博. 初治弥漫大B细胞淋巴瘤患者血清白细胞介素-6水平及其预后意义 [J]. 国际医药卫生导报, 2025, 31(7): 1179-1183.
[3]	朱鹏唐文玲覃刚. 结直肠癌中微小RNA功能及临床价值进展 [J]. 国际医药卫生导报, 2025, 31(6): 886-890.
[4]	于明英李媛燕普. 3D和2D腹腔镜手术治疗胃肠道癌症患者的短期预后比较 [J]. 国际医药卫生导报, 2025, 31(6): 900-907.
[5]	潘文昕姜伟炜. 结肠镜检查时机对缺血性结肠炎患者预后影响的研究进展 [J]. 国际医药卫生导报, 2025, 31(6): 914-917.
[6]	郭玉格刘维帅马平丽. 子宫内膜癌组织中增殖基因表达情况与患者病理及预后的关系 [J]. 国际医药卫生导报, 2025, 31(6): 954-959.
[7]	文斐岑瑞祥. 3-磷酸甘油醛脱氢酶在喉部鳞状细胞癌中的功能及临床意义 [J]. 国际医药卫生导报, 2025, 31(6): 965-972.
[8]	谢紫阳姜小建孙佳折彦儒. 原发性肺癌患者血清非编码长链RNA及微RNA表达水平与预后的关系 [J]. 国际医药卫生导报, 2025, 31(6): 983-989.
[9]	赵金鹏高呈飞吕晓东. 浸润性非小细胞肺癌患者水平裂分化情况及肿瘤边缘-水平裂距离与预后的关系 [J]. 国际医药卫生导报, 2025, 31(5): 761-765.
[10]	刘珍珍刘谩贾永庆杨美菊. miR-6884-5p在非小细胞肺癌中的表达及与肿瘤标志物的相关性 [J]. 国际医药卫生导报, 2025, 31(5): 766-770.
[11]	张君高伟吕金鹏仲莉梅. 血清miRNA生物标志物预测鼻咽癌患者临床预后的价值 [J]. 国际医药卫生导报, 2025, 31(2): 303-307.
[12]	杨丽丽王灿灿李翡王海静齐巧霞雷莉妍贺丰杰. 自噬相关标志物对子宫内膜癌患者生存预后的预测价值及对化疗效果的影响[J]. 国际医药卫生导报, 2025, 31(1): 30-37.
[13]	董思颖李俊超闫松. 多模态磁共振成像预测新生儿缺氧缺血性脑病预后的价值分析 [J]. 国际医药卫生导报, 2025, 31(1): 84-88.
[14]	杨启梅李维阁. 血清半胱氨酸天冬氨酸蛋白酶3和可溶性血管内皮生长因子受体-1水平与突发性耳聋患者病情及预后的关系分析 [J]. 国际医药卫生导报, 2025, 31(1): 99-104.
[15]	马利军刘占军韩继明. miR-150-5p、miR-135b在糖尿病肾病患者中的表达及意义 [J]. 国际医药卫生导报, 2024, 30(9): 1454-1459.